Fragment 176-191

Overview and Mechanism of Action

Fragment 176-191, commonly designated HGH Frag 176-191 or simply "HGH Fragment," is a synthetic peptide corresponding to the C-terminal 16 amino acids (positions 176 through 191) of the 191-amino-acid human growth hormone (hGH) molecule. The sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, and the two cysteine residues at positions 182 and 189 (relative to the full hGH sequence) form a disulfide bond that maintains a helical conformation of the fragment within this region, mirroring the structural arrangement found in the intact hGH molecule.

The research interest in this fragment arises from studies in the 1990s and early 2000s that sought to identify which structural domain of hGH was responsible for its lipolytic (fat-mobilizing) activity, as distinct from its growth-promoting (anabolic) and diabetogenic effects mediated through GH receptor binding and IGF-1 axis stimulation. Full-length hGH exerts lipolytic effects on adipose tissue via the beta-3 adrenergic signaling cascade, promoting triglyceride hydrolysis and fatty acid release, but these effects are accompanied at therapeutic doses by insulin resistance, sodium retention, carpal tunnel, and other side effects mediated through the same GH receptor signaling that drives anabolic and growth-promoting effects. The identification of a C-terminal fragment that retained lipolytic activity without engaging the GH receptor would, in theory, allow adipose-specific metabolic effects to be studied in isolation.

Research from the laboratory of Ken Ho at the Garvan Institute in Sydney, Australia, demonstrated that hGH Fragment 176-191 stimulated lipolysis in isolated rat adipocytes and in intact rodents without detectable engagement of the GH receptor, insulin resistance, or the growth-promoting activities of full-length hGH. The proposed mechanism involves interaction with a distinct, non-GH receptor molecular target on adipocyte plasma membranes, though the precise receptor identity and signaling cascade remain areas of ongoing investigation. The disulfide-constrained helical conformation of the fragment within this region has been proposed to be critical for its activity, as linearized or reduced versions of the fragment show attenuated effects in some experimental systems.

Research History and Development

Systematic mapping of hGH's lipolytic domain was prompted by the clinical observation that hGH administration produced body composition changes (reduced fat mass, increased lean mass) of clinical interest, but that these effects were inseparable from insulin resistance and other hGH receptor-mediated effects at doses producing meaningful adipose effects. The strategic interest in isolating the lipolytic activity into a smaller, receptor-selective fragment drove the structure-activity relationship work that identified the 176-191 region.

A key publication by Ng et al. in the Journal of Endocrinology reported that the C-terminal hGH fragment stimulated lipolysis in 3T3-L1 adipocyte cell cultures and in vivo in rodents without producing effects on insulin sensitivity or growth. Subsequent research from Australian groups examined the fragment's effects on fat mass, body composition, and metabolic rate in rodent models of obesity. The compound was advanced to human Phase 1 clinical trials by Metabolic Pharmaceuticals (Melbourne, Australia) in the early 2000s, where it was administered by subcutaneous injection or oral route in healthy overweight volunteers, with reported reductions in body fat mass over treatment periods of 12 weeks.

Typical Research Parameters

In in vitro lipolysis assays using 3T3-L1 adipocytes or primary rat adipocytes, hGH Fragment 176-191 is typically tested at concentrations ranging from 1 nM to 100 nM, with glycerol release into the culture medium as the primary endpoint for lipolysis quantification. In vivo rodent studies have employed subcutaneous or intraperitoneal doses of 250–500 mcg/kg, with body composition, fat pad mass, and plasma free fatty acid concentrations as standard endpoints. The absence of GH receptor engagement should be confirmed in each experimental system through appropriate receptor binding assays or IGF-1 measurement (which, if elevated, would indicate GH receptor activity via hepatic IGF-1 production). For research use only.

Storage Requirements

HGH Fragment 176-191 contains a disulfide bond that is essential to its biological activity and must be preserved during storage and handling. Lyophilized powder should be stored at -20°C, protected from reducing agents, metal ions, and light. Reconstitution should use sterile water or saline that has been degassed or sparged with nitrogen to minimize dissolved oxygen, which can catalyze disulfide scrambling. Store reconstituted solutions at 2–8°C and use within 14–21 days. Avoid exposure to reducing agents (DTT, beta-mercaptoethanol, TCEP) which would cleave the disulfide and inactivate the fragment. HPLC verification of the oxidized (disulfide-intact) form is recommended before quantitative experiments.

Safety Notes and Research Considerations

HGH Fragment 176-191's reported GH receptor independence, if confirmed in the specific experimental system being studied, substantially narrows the expected off-target effect profile compared to full-length hGH. However, researchers should independently verify receptor selectivity in their model systems rather than relying solely on published data from different cell or animal types. The disulfide bond introduces a stability variable not present in linear peptides, and researchers should verify fragment integrity after any storage perturbation. This material is provided for research purposes only and is not approved for human therapeutic or veterinary use.